Search
Entrada Therapeutics Inc
TRDAAdd to Watchlist
5.480USD
+0.100+1.86%
Close 10-05 16:00（ET）
212.73MMarket Cap
LossP/E TTM
Entrada Therapeutics Inc (TRDA) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Entrada Therapeutics Inc in the past month.
Buy
3 Strong Buy
4 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
16.648USD+209.44%
TRDA Analyst Recommendation Trends
In the current month, TRDA has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. TRDA average Analyst price target in the last month is 16.648.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
3
3
3
3
3
2
1
1
4
4
5
4
4
4
4
4
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
7
7
6
5
5
TRDA Analyst Rating for Peer Comparison
Updated: Oct 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Insmed Inc
INSM
7
18
0
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Financial Forecasting
Based on analysts' estimates, TRDA EPS is projected to reach -1.010 in FY2026Q3, following reported EPS of -1.013 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.15
-1.04
-1.05
-1.01
-0.93
Actual
-0.94
-0.95
-1.01
--
--
Surprise
+18.15%
+8.43%
+3.54%
--
--
FAQs
What is Entrada Therapeutics Inc's expected revenue for the next quarter?
Entrada Therapeutics Inc's expected revenue is 5.26M.
What is Entrada Therapeutics Inc's price target?
Analysts forecast that Entrada Therapeutics Inc's price target is USD 16.65, with the highest forecast at USD 25.00 and the lowest forecast at USD 7.24.
How have Entrada Therapeutics IncTRDA's recent earnings per share performed?
The market expectation was USD -1.01, while Entrada Therapeutics IncTRDA's earnings per share (EPS) for the previous quarter was USD -0.95. EPS for the next quarter is expected at USD -1.01.
What is the analyst rating for Entrada Therapeutics Inc?
Based on the ratings of Entrada Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.